Page last updated: 2024-10-30

methantheline and Hyperhidrosis

methantheline has been researched along with Hyperhidrosis in 13 studies

Methantheline: A quaternary ammonium compound that acts as an antimuscarinic agent. It has been used in the treatment of PEPTIC ULCER, in gastrointestinal disorders associated with smooth muscle spasm, and in the management of urinary incontinence, and may also be used for the treatment of HYPERHIDROSIS.

Hyperhidrosis: Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy and safety of methantheline bromide (MB) in the treatment of axillary and palmar-axillary hyperhidrosis."9.17Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. ( Berensmeier, A; Dirschka, T; Fischer, T; Hamm, H; Müller, C; Reich, K; Rzany, B, 2013)
"To assess the efficacy and safety of methantheline bromide (MB) in the treatment of axillary and palmar-axillary hyperhidrosis."5.17Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial. ( Berensmeier, A; Dirschka, T; Fischer, T; Hamm, H; Müller, C; Reich, K; Rzany, B, 2013)
" No serious adverse events were reported."2.71[Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis]. ( Hund, M; Rzany, B; Sinkgraven, R, 2004)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19905 (38.46)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's6 (46.15)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jäger-Becker, D1
Müller, C2
Augustin, M1
Berensmeier, A1
Hamm, H1
Dirschka, T1
Reich, K1
Fischer, T1
Rzany, B3
ZUPKO, AG2
PROKOP, LN1
ROBINSON, HM1
AMYOT, R1
GRIMSON, KS1
LYONS, CK1
WATKINS, WT1
CALLAWAY, JL1
Hund, M1
Sinkgraven, R1
Fuchslocher, M1

Trials

2 trials available for methantheline and Hyperhidrosis

ArticleYear
Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2013, Volume: 27, Issue:10

    Topics: Adolescent; Adult; Aged; Axilla; Dose-Response Relationship, Drug; Double-Blind Method; Female; Huma

2013
[Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2004, Volume: 2, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Cholinergic Antagonists; Double-Blind Method; Female; Germa

2004

Other Studies

11 other studies available for methantheline and Hyperhidrosis

ArticleYear
[In process].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:8

    Topics: Administration, Oral; Axilla; Drug Approval; Germany; Humans; Hyperhidrosis; Methantheline; Muscarin

2016
[Hyperhidrosis - an underestimated comorbidity. Great discomfort should not be tolerated].
    MMW Fortschritte der Medizin, 2014, Apr-17, Volume: 156, Issue:7

    Topics: Adult; Comorbidity; Female; Germany; Guideline Adherence; Humans; Hyperhidrosis; Male; Methantheline

2014
[Hyperhidrosis. Effective reduced sweating with methantheline bromide].
    MMW Fortschritte der Medizin, 2012, May-31, Volume: 154, Issue:10

    Topics: Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Guideline Adherence; Humans;

2012
Willingness-to-pay and patient-defined benefits in the treatment of hyperhidrosis: results from the first German health services research study in hyperhidrosis.
    The British journal of dermatology, 2013, Volume: 168, Issue:2

    Topics: Dermatologic Agents; Financing, Personal; Germany; Health Care Surveys; Humans; Hyperhidrosis; Metha

2013
[Managing hyperhidrosis].
    MMW Fortschritte der Medizin, 2012, Jun-28, Volume: 154, Issue:12

    Topics: Aluminum Chloride; Aluminum Compounds; Astringents; Botulinum Toxins, Type A; Bridged-Ring Compounds

2012
A comparative study of prantal and banthine in hyperhidrosis.
    Journal of the American Pharmaceutical Association. American Pharmaceutical Association, 1952, Volume: 41, Issue:12

    Topics: Humans; Hyperhidrosis; Methantheline; Parasympatholytics; Piperidines; Quaternary Ammonium Compounds

1952
A treatment for hyperhidrosis.
    Bulletin of the School of Medicine (Baltimore, Md.), 1953, Volume: 38, Issue:3

    Topics: Humans; Hyperhidrosis; Methantheline; Quaternary Ammonium Compounds; Sweating

1953
[Recent medications in the control of perspiration odor and hyperhidrosis].
    L'union medicale du Canada, 1951, Volume: 80, Issue:2

    Topics: Chlorophyll; Humans; Hyperhidrosis; Methantheline; Odorants; Quaternary Ammonium Compounds; Sweat; S

1951
An evaluation of banthine in hyperhidrosis.
    Journal of the American Pharmaceutical Association. American Pharmaceutical Association, 1952, Volume: 41, Issue:4

    Topics: Hyperhidrosis; Methantheline; Parasympatholytics; Quaternary Ammonium Compounds; Sweating

1952
Successful treatment of hyperhidrosis using banthine.
    Journal of the American Medical Association, 1950, Aug-12, Volume: 143, Issue:15

    Topics: Humans; Hyperhidrosis; Methantheline; Quaternary Ammonium Compounds; Sweat Glands

1950
[Oral anticholinergic therapy of focal hyperhidrosis with methanthelinium bromide (Vagantin). Initial data on effectiveness].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2002, Volume: 53, Issue:2

    Topics: Administration, Oral; Cholinergic Antagonists; Dose-Response Relationship, Drug; Drug Administration

2002